Update on TNF Inhibitors

被引：4
作者：
Kerdel, Francisco A. [1 ,2 ]
机构：
[1] Larkin Community Hosp, Inpatient Dermatol, Miami, FL USA
[2] Florida Int Univ, Herbert Wertheim Coll Med, Dept Dermatol, Miami, FL 33199 USA
来源：
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2016年 / 35卷
关键词：
Efficacy; investigational agents; psoriasis; psoriatic arthritis; safety; tumor necrosis factor inhibitors; PLACEBO-CONTROLLED TRIAL; SEVERE PLAQUE PSORIASIS; OPEN-LABEL; PHASE-III; CERTOLIZUMAB PEGOL; INFUSION REACTIONS; VS; METHOTREXATE; EFFICACY; MODERATE; SAFETY;
D O I：
10.12788/j.sder.2016.019
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
The introduction of tumor necrosis factor (TNF)-alpha inhibitors dramatically improved the management of psoriasis. Some newer or investigational biologics with different mechanisms of action have demonstrated noninferiority or superiority to etanercept, the first self-injectable anti-TNF-alpha agent to become available in the United States. Nonetheless, TNF-alpha inhibitors are likely to remain a mainstay of therapy for many years. (C) 2016 published by Frontline Medical Communications.
引用
收藏
页码：S67 / S70
页数：4
相关论文
共 37 条
  • [1] [Anonymous], 2016, CIMZ PACK INS
  • [2] [Anonymous], 2016, SIMP PACK INS
  • [3] [Anonymous], 2015, REM PACK INS
  • [4] [Anonymous], 2016, COS PACK INS
  • [5] [Anonymous], 2015, ENBR PACK INS
  • [6] [Anonymous], 2016, HUM PACK INS
  • [7] Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
    Bachelez, Herve
    van de Kerkhof, Peter C. M.
    Strohal, Robert
    Kubanov, Alexey
    Valenzuela, Fernando
    Lee, Joo-Heung
    Yakusevich, Vladimir
    Chimenti, Sergio
    Papacharalambous, Jocelyne
    Proulx, James
    Gupta, Pankaj
    Tan, Huaming
    Tawadrous, Margaret
    Valdez, Hernan
    Wolk, Robert
    [J]. LANCET, 2015, 386 (9993) : 552 - 561
  • [8] Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)
    Barker, J.
    Hoffmann, M.
    Wozel, G.
    Ortonne, J. -P.
    Zheng, H.
    van Hoogstraten, H.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) : 1109 - 1117
  • [9] Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry
    Choquette, Denis
    Faraawi, Rafat
    Chow, Andrew
    Rodrigues, Jude
    Bensen, William J.
    Nantel, Francois
    [J]. JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1105 - 1111
  • [10] Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy
    Gordon, KB
    Gottlieb, AB
    Leonardi, CL
    Elewski, BE
    Wang, A
    Jahreis, A
    Zitnik, R
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2006, 17 (01) : 9 - 17
1234